Scale Squeeze Patents: Top Companies & Filing Trends 2026
- Concentrated at the top. The top 5 assignees hold 65.3% of all 95 records in scope, and the top 10 hold 88.4% — a short list of names controls most of the filed art.
- Filing has cooled from its 2020 peak. 2020 was the high-water year at 18 filings; by the 2021-to-2024 span tracked here, filings fell 33%, from 6 to 4.
- Materials claims dominate the mechanism. 81.1% of the 95 records sit in C09K (materials for miscellaneous applications), far ahead of E21B well-operations claims at 45.3%.
Filing growth compares 2021 (6 records) with 2024 (4) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 95 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent families addressing scale squeeze treatments and related chemical remediation methods — the injection of scale inhibitor into a formation for later slow release, plus adjacent work on organic deposit removal, minimum inhibitor concentration control, and adsorption isotherm modelling. The scope also captures barium sulfate scale management,
95 published records fall within scope from 2015 through the 2026-07-31 data cut-off. Because publication typically lags filing by around 18 months, the most recent one to two years in any trend understate actual filing activity and should be read as still filling in.
Filing trend and technology composition
Two views of the same 95 records: how filing activity has moved year over year, and which IPC subclasses carry the claims.
Filing trend, 2017 to 2026
Filings rose from 2 in 2017 to a peak of 18 in 2020, then eased off. Over the last complete three-year span tracked here, 2021 to 2024, filings fell from 6 to 4, a 33% decline — read the 2025-2026 tail as incomplete rather than as a continuation of that drop.
IPC subclass composition
C09K (materials for miscellaneous applications) appears in 81.1% of the 95 records, well ahead of E21B (earth and rock drilling / wells) at 45.3% and C02F (water and wastewater treatment) at 25.3%. Smaller shares in G01N, C07F, C07C, C08F and C23F mark narrower, less-claimed mechanisms. Because a single record can carry several IPC classes, these shares add to more than 100% and should not be summed.
Shares are the percentage of the 95 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Scale Squeeze and Chemical Remediation with Eureka
This page is one run against one query. Ask Eureka your own question about scale squeeze and chemical remediation and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this field
Preflush chemicals for scale inhibitor squeeze (US20170260441A1)
A method and system for removing water from the near wellbore during scale inhibitor squeeze treatments.Filed by ConocoPhillips, published 2017-09-14. It sits inside the largest single technology cluster in this dataset — treatment-preparation chemistry ahead of the inhibitor stage itself.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5018577A | Phosphinate inhibitor for scale squeeze applications | 140 |
| 2 | US4602683A | Method of inhibiting scale in wells | 48 |
| 3 | US6913081B2 | Combined scale inhibitor and water control treatments | 41 |
| 4 | US20080257551A1 | Methods of Chemical Diversion of Scale Inhibitors | 26 |
| 5 | US20040154799A1 | Combined scale inhibitor and water control treatments | 26 |
| 6 | US20140338915A1 | Particles containing one or more controlled release cross-linked active agents | 25 |
| 7 | US10287482B2 | Particles containing one or more controlled release cross-linked active agents | 10 |
| 8 | US20220098970A1 | System for optimization of hydrocarbon production | 7 |
| 9 | US20220120159A1 | Enhanced scale inhibitor squeeze treatment using a chemical additive | 5 |
| 10 | US20170260441A1 | Preflush chemicals for scale inhibitor squeeze | 5 |
Citation counts reflect influence within this searched corpus and skew toward older filings; they are not a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Read together, the concentration, trend and technology figures point to a field where claim space is occupied at the core and thinning fast at the edges.
A short list controls most of the art
The top 5 assignees account for 65.3% of all 95 records in scope, and the top 10 climb to 88.4%. That leaves a long tail of single- or few-filing entrants competing for the remaining share, which makes freedom-to-operate checks against the leaders the first move for any new entrant.
Activity has cooled from its 2020 high
Filings peaked at 18 in 2020 and, across the last complete three-year window tracked here (2021 to 2024), fell 33% from 6 to 4. The 2025-2026 tail is still filling in given publication lag, so this should be read as a cooling from an unusually active year rather than a collapsing field.
Materials chemistry, not well mechanics, carries the claims
C09K (materials for miscellaneous applications) touches 81.1% of the 95 records, far outweighing E21B well-operations claims at 45.3%. Formulation and inhibitor-chemistry claims are where the field is most densely staked; mechanical deployment methods have comparatively more room.
Cross-filing is limited and clustered
Only 8 co-assignee pairs appear across the dataset, with the strongest pairing tying a major services company to a national oil company. Most records are filed by a single assignee, so joint development is the exception rather than the norm in this field.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to scale squeeze and chemical remediation, with the prior art for and against each one.
Who holds the claim space
Filing activity concentrates around a small group of oilfield services majors and chemical suppliers, with national oil companies appearing mainly as co-filers rather than solo applicants.
One filer well ahead of the field
The leading assignee holds 20 of the 95 records in scope, roughly triple the fifth-place count of 7. That gap is the clearest signal in the ranking: a single filer has built a substantially deeper portfolio than any peer.
A cluster forms behind the leader
From fifth place at 7 records down to tenth place at 3, filing counts fall off quickly, forming a mid-field of oilfield chemical and services firms rather than a second dominant player.
Services-and-operator pairings are the main link
The strongest co-assignee pairing in the dataset links a major oilfield services provider with a national oil company at 3 shared filings, with a smaller pairing between two chemical suppliers. These links suggest field-trial or joint-development arrangements rather than broad industry consortia.
| Assignee | Recent year | YoY |
|---|---|---|
| Akzo Nobel Chemicals International BV | 0 | — |
| Halliburton Energy Services, Inc. | 0 | — |
| ConocoPhillips Company | 0 | — |
| Nalco Company | 0 | — |
| NOV PROCESS & FLOW TECH AS | 0 | — |
| Saudi Arabian Oil Co. (Saudi Aramco) | 0 | — |
| Baker Hughes Oilfield Operations LLC | 0 | — |
| CORSICANA TECHNOLOGIES INC | 0 | — |
Where to take this analysis
The dataset points to a field with an occupied core and a thinning edge. Two directions follow from that.
Check freedom-to-operate against the leader first
With one assignee holding 20 of 95 records and the top 5 covering 65.3%, any new filing in core inhibitor chemistry should be checked against that leader's portfolio before anywhere else.
Run a freedom-to-operate scan in EurekaWatch the smaller IPC branches for openings
Classes like C07F, C07C, C08F and C23F each sit at 3.2% or below of the 95 records — thin enough that a well-drafted claim in adsorption isotherm work or organo-metallic inhibitor chemistry may still find open space.
Explore white space with EurekaCommon questions on scale squeeze patents
Filing activity in this field concentrates heavily at the top: the leading assignee holds 20 of the 95 records in scope, and the top 5 assignees together account for 65.3% of all records. The top 10 climb to 88.4%, leaving a long tail of companies with only a handful of filings each. Most leaders are oilfield services and specialty chemical companies rather than pure operators, reflecting that inhibitor formulation, not well mechanics, carries most of the claim weight.
Filing peaked at 18 records in 2020 and has since eased; across the last complete three-year window, 2021 to 2024, filings fell 33%, from 6 to 4. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are still incomplete and should not be read as confirming a continued decline. The honest read is a cooling from an unusually active 2020 rather than a field in collapse.
C09K, covering materials for miscellaneous applications, appears in 81.1% of the 95 records in scope, making inhibitor and treatment-chemistry formulation the densest claim area by far. E21B, earth and rock drilling and well operations, follows at 45.3%, and C02F water treatment claims appear in 25.3%. Because a record can carry multiple IPC classes, these figures do not sum to 100% and should be read as independent shares of the same 95-record base.
US20170260441A1, filed by ConocoPhillips and published 2017-09-14, describes preflush chemicals used to remove water from the near-wellbore region ahead of a scale inhibitor squeeze treatment. It sits within the broader preparation-chemistry space that precedes the inhibitor placement step itself, rather than the inhibitor formulation or the shut-in mechanics. Anyone designing a squeeze preflush step should review its specific claim language before assuming a similar preparation method is open to file.
The smaller IPC branches in this dataset — organo-metallic inhibitor chemistry (C07F) at 3.2% of records, and single-record shares in C07C, C08F and C23F — carry far fewer filings than the dominant C09K and E21B classes. Adsorption isotherm modelling for minimum inhibitor concentration prediction and asphaltene solvent soak formulations also appear thinly represented relative to the core inhibitor-squeeze mechanism. These are the areas worth a targeted freedom-to-operate check rather than a full landscape review, since claim density there is measurably lower.
Research Scale Squeeze and Chemical Remediation in depth with Eureka
Go past this page: query the whole scale squeeze and chemical remediation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.